S. Swerdlow, E. Campo, N. Harris, E. Jaffe, S. Pileri et al., WHO Classification of Tumours of Haematopoetic and Lymphoid Tissue, International Agency for Research on Cancer (IARC), 2008.

T. Barbui, J. Thiele, H. Gisslinger, G. Finazzi, A. Vannucchi et al., The 2016 revision of WHO classification of myeloproliferative neoplasms: Clinical and molecular advances, Blood Reviews, vol.30, issue.6, pp.453-459, 2016.
DOI : 10.1016/j.blre.2016.06.001

E. Baxter, L. Scott, P. Campbell, C. East, N. Fourouclas et al., Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders, The Lancet, vol.365, issue.9464, pp.1054-1061, 2005.
DOI : 10.1016/S0140-6736(05)74230-6

C. James, V. Ugo, L. Couedic, J. Staerk, J. Delhommeau et al., A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera, Nature, vol.100, issue.suppl. 1, pp.1144-1148, 2005.
DOI : 10.1182/blood-2002-09-2839

R. Kralovics, F. Passamonti, A. Buser, S. Teo, R. Tiedt et al., in Myeloproliferative Disorders, New England Journal of Medicine, vol.352, issue.17, pp.1779-1790, 2005.
DOI : 10.1056/NEJMoa051113

J. Lee, S. Gabriel, T. Mercher, D. Andrea, A. Frohling et al., Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis, Cancer Cell, vol.7, pp.387-397, 2005.

K. Kaushansky, On the molecular origins of the chronic myeloproliferative disorders: it all makes sense, Blood, vol.105, issue.11, pp.4187-4190, 2005.
DOI : 10.1182/blood-2005-03-1287

A. Pardanani, T. Lasho, C. Finke, C. Hanson, and A. Tefferi, Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera, Leukemia, vol.365, issue.9, 2007.
DOI : 10.1016/S0140-6736(05)71142-9

L. Scott, W. Tong, R. Levine, M. Scott, P. Beer et al., Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis, JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis, pp.459-468, 2007.
DOI : 10.1056/NEJMoa065202

T. Er, S. Lin, J. Chang, L. Hsieh, S. Lin et al., Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation, Clinica Chimica Acta, vol.408, issue.1-2, pp.39-44, 2009.
DOI : 10.1016/j.cca.2009.07.002

G. Zapparoli, R. Jorissen, C. Hewitt, M. Mcbean, D. Westerman et al., Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2V617F mutant allele detection, BMC Cancer, vol.35, issue.1, p.206, 2013.
DOI : 10.1093/nar/gkm671

URL : https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-13-206?site=bmccancer.biomedcentral.com

M. Cankovic, L. Whiteley, R. Hawley, R. Zarbo, and D. Chitale, V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory, American Journal of Clinical Pathology, vol.132, issue.5, pp.713-721, 2009.
DOI : 10.1038/sj.leu.2404955

P. Lundberg, A. Karow, R. Nienhold, R. Looser, H. Hao-shen et al., Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms, Blood, vol.123, issue.14, pp.2220-2228, 2014.
DOI : 10.1182/blood-2013-11-537167

A. Tefferi, J. Thiele, A. Vannucchi, and T. Barbui, An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms, Leukemia, vol.9, issue.7, pp.1407-1413, 2014.
DOI : 10.1136/jcp.55.11.862

J. Broseus, J. Park, S. Carillo, S. Hermouet, and F. Girodon, Presence of calreticulin mutations in JAK2-negative polycythemia vera, Blood, vol.124, issue.26, pp.3964-3966, 2014.
DOI : 10.1182/blood-2014-06-583161

J. Ha and Y. Kim, Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms, Annals of Laboratory Medicine, vol.35, issue.1, pp.22-27, 2015.
DOI : 10.3343/alm.2015.35.1.22

URL : http://europepmc.org/articles/pmc4272961?pdf=render

S. Kim, K. Im, S. Park, J. Kwon, J. Kim et al., CALR, JAK2, and MPL Mutation Profiles in Patients With Four Different Subtypes of Myeloproliferative Neoplasms: Primary Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera, and Myeloproliferative Neoplasm, Unclassifiable, American Journal of Clinical Pathology, vol.143, issue.5, pp.635-644, 2015.
DOI : 10.1309/AJCPUAAC16LIWZMM

J. Wang, J. Hao, N. He, J. C. Ma, and D. , The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia, Turkish Journal of Hematology, vol.33, issue.3, pp.180-186, 2016.
DOI : 10.4274/tjh.2015.0220

R. Chaligne, C. James, C. Tonetti, R. Besancenot, L. Couedic et al., Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis, Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis, pp.3735-3743, 2007.
DOI : 10.1182/blood-2007-05-089003

A. Pardanani, R. Levine, T. Lasho, Y. Pikman, R. Mesa et al., MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients, Blood, vol.108, issue.10, pp.3472-3476, 2006.
DOI : 10.1182/blood-2006-04-018879

A. Pardanani, T. Lasho, C. Finke, and A. Tefferi, Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis, American Journal of Hematology, vol.86, issue.8, pp.701-702, 2011.
DOI : 10.1002/ajh.22058

P. Beer, P. Campbell, L. Scott, A. Bench, W. Erber et al., MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort, Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by highresolution melting analysis, pp.141-149, 2008.
DOI : 10.1182/blood-2008-01-131664

R. Nussenzveig, H. Pham, S. Perkins, J. Prchal, A. Agarwal et al., allelic burden, Leukemia & Lymphoma, vol.57, issue.6, pp.1429-1435, 2016.
DOI : 10.1038/sj.leu.2405097

D. Pietra, A. Brisci, E. Rumi, S. Boggi, C. Elena et al., Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms, Haematologica, vol.96, issue.4, pp.607-611, 2011.
DOI : 10.3324/haematol.2010.034793

V. Ugo, S. Tondeur, M. Menot, N. Bonnin, L. Gac et al., Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients, PLoS ONE, vol.5, issue.1, p.8893, 2010.
DOI : 10.1371/journal.pone.0008893.t001

D. Bodian, J. Mccutcheon, P. Kothiyal, K. Huddleston, R. Iyer et al., Germline Variation in Cancer-Susceptibility Genes in a Healthy, Ancestrally Diverse Cohort: Implications for Individual Genome Sequencing, PLoS ONE, vol.265, issue.4, p.94554
DOI : 10.1371/journal.pone.0094554.s002

K. Hussein, O. Bock, K. Theophile, N. Von-neuhoff, T. Buhr et al., (V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis, Exp Hematol, vol.37, pp.21186-1193, 2009.

J. Kittur, R. Knudson, T. Lasho, C. Finke, N. Gangat et al., Clinical correlates ofJAK2V617F allele burden in essential thrombocythemia, Cancer, vol.130, issue.11, pp.2279-2284, 2007.
DOI : 10.1016/S0140-6736(05)71142-9

URL : http://onlinelibrary.wiley.com/doi/10.1002/cncr.22663/pdf

A. Tefferi, J. Strand, T. Lasho, R. Knudson, C. Finke et al., Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera, Leukemia, vol.21, issue.9, pp.2074-2075, 2007.
DOI : 10.1038/sj.leu.2404500

URL : http://www.nature.com/leu/journal/v21/n9/pdf/2404724a.pdf

A. Vannucchi, E. Antonioli, P. Guglielmelli, A. Pardanani, and A. Tefferi, Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal, Leukemia, vol.21, issue.7, pp.1299-1307, 2008.
DOI : 10.1182/blood-2007-01-066985

E. Antonioli, P. Guglielmelli, G. Poli, C. Bogani, A. Pancrazzi et al., Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia, Myeloproliferative Disorders Research C: Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia, pp.41-48, 2008.
DOI : 10.3324/haematol.11653

S. Park, H. Chi, Y. Cho, S. Jang, and C. Park, V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm, Blood Research, vol.48, issue.2, pp.128-132, 2013.
DOI : 10.5045/br.2013.48.2.128

G. Fontanelli, C. Barate, E. Ciabatti, F. Guerrini, S. Grassi et al., mutation in Philadelphia-negative chronic myeloproliferative neoplasms, International Journal of Laboratory Hematology, vol.40, issue.6, pp.766-773, 2015.
DOI : 10.1093/nar/gks203

X. Wu, J. Lee, D. Peker, S. Spitzer, J. Laser et al., Is Low Positive JAK2 V617F Mutation Test Result Clinically Significant?, Applied Immunohistochemistry & Molecular Morphology, vol.24, issue.8, pp.589-594, 2016.
DOI : 10.1097/PAI.0000000000000228

URL : https://academic.oup.com/ajcp/article-pdf/138/suppl_2/A357/18136290/ajcpath138-167.pdf

M. Borowczyk, M. Wojtaszewska, K. Lewandowski, L. Gil, M. Lewandowska et al., The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms, Thrombosis Research, vol.135, issue.2, pp.272-280, 2015.
DOI : 10.1016/j.thromres.2014.11.006

Y. Liu, C. Liu, N. He, M. Wang, X. Zhang et al., JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm, Zhonghua Xue Ye Xue Za Zhi, vol.36, pp.191-195, 2015.